We are proud to announce that Nugene Pharma (Hangzhou) has officially obtained the Chinese invention patent CN119752714A, for a proprietary strain capable of high-yield production of Pyrroloquinoline Quinone (PQQ) via microbial fermentation.
Key Innovation
Our R&D team has successfully identified and induced a high-performance strain:
Hyphomicrobium denitrificans HXRD10‑32,
now preserved in the China Center for Type Culture Collection (CCTCC No: M 20242618).
Coupled with advanced fermentation optimization—including carbon source modulation, microelement feeding strategies, and DO regulation—we’ve significantly enhanced the biosynthesis efficiency of PQQ in microbial systems.
Comparable Pathway, Different Strain
While our microbial approach shares a similar metabolic pathway with Mitsubishi’s industrial production model in Japan, we emphasize that our strain is independently selected and developed by Nugene Pharma, ensuring high performance, regulatory safety, and full IP control.
IP Use Advisory
If any downstream partners wish to refer to our patent (CN119752714A) on product packaging or promotional materials, please contact us in advance for authorization. Proper licensing ensures brand integrity and intellectual property compliance.
Next Step: Enabling the Future of PQQ
With strong biological productivity and clear regulatory safety, PQQ is rapidly becoming a premium ingredient in functional foods, dietary supplements, cosmetics, and health beverages. At Nugene Pharma, we are committed to pushing the boundaries of microbial synthesis to empower clean-label, science-backed health products.
Let’s connect!
Interested in co-developing PQQ-based solutions or learning more about our microbial fermentation technologies? Message us directly or email: bd1@nugene.com.cn